Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Expected to Announce Earnings of -$0.63 Per Share

Analysts predict that Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) will announce earnings of ($0.63) per share for the current quarter, according to Zacks. Six analysts have made estimates for Karyopharm Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.77). Karyopharm Therapeutics posted earnings per share of ($0.77) in the same quarter last year, which indicates a positive year-over-year growth rate of 18.2%. The business is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Karyopharm Therapeutics will report full year earnings of ($2.21) per share for the current year, with EPS estimates ranging from ($2.49) to ($1.96). For the next financial year, analysts expect that the business will report earnings of ($1.51) per share, with EPS estimates ranging from ($2.09) to ($0.58). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Karyopharm Therapeutics.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last released its earnings results on Tuesday, February 8th. The company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.86. The business had revenue of $126.27 million for the quarter, compared to analysts’ expectations of $55.98 million. During the same period last year, the firm earned ($0.59) EPS.

KPTI has been the topic of several research analyst reports. Canaccord Genuity Group decreased their target price on Karyopharm Therapeutics from $20.00 to $10.00 in a report on Monday, April 11th. StockNews.com assumed coverage on Karyopharm Therapeutics in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reduced their target price on Karyopharm Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, March 18th. Royal Bank of Canada reduced their target price on Karyopharm Therapeutics from $12.00 to $8.00 and set a “sector perform” rating for the company in a research note on Tuesday, March 8th. Finally, SVB Leerink dropped their price target on Karyopharm Therapeutics from $8.00 to $6.00 and set a “market perform” rating for the company in a report on Wednesday, March 2nd. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Karyopharm Therapeutics presently has a consensus rating of “Hold” and an average price target of $11.57.

Shares of NASDAQ KPTI traded up $0.07 during trading hours on Wednesday, reaching $6.79. The stock had a trading volume of 58,862 shares, compared to its average volume of 3,458,590. The business’s fifty day moving average is $8.13 and its two-hundred day moving average is $7.60. Karyopharm Therapeutics has a twelve month low of $4.42 and a twelve month high of $14.73.

In other news, Director Michael Kauffman sold 6,764 shares of the company’s stock in a transaction dated Monday, February 7th. The shares were sold at an average price of $9.86, for a total transaction of $66,693.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Mason sold 3,947 shares of the business’s stock in a transaction that occurred on Monday, February 7th. The shares were sold at an average price of $9.86, for a total value of $38,917.42. The disclosure for this sale can be found here. Insiders have sold 19,122 shares of company stock worth $188,543 over the last three months. Insiders own 10.24% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of KPTI. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Karyopharm Therapeutics by 78.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,641 shares of the company’s stock worth $78,000 after acquiring an additional 4,664 shares in the last quarter. American Trust acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $81,000. Walleye Capital LLC acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $89,000. AlphaCentric Advisors LLC acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $900,000. Finally, Barclays PLC boosted its stake in Karyopharm Therapeutics by 37.3% during the fourth quarter. Barclays PLC now owns 181,752 shares of the company’s stock worth $1,169,000 after buying an additional 49,363 shares during the last quarter. 77.07% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics (Get Rating)

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

Recommended Stories